Melatonin quitiapine resperidobe overdose management
| Drug | Primary Mechanism | Key Toxicity |
|---|---|---|
| Quetiapine | D2/5-HT2A antagonist, H1, muscarinic, α1 blockade | CNS depression, QT prolongation, hypotension, antimuscarinic toxidrome |
| Risperidone | D2/5-HT2A antagonist, α1 blockade | CNS depression, EPS, QT prolongation, hypotension |
| Melatonin | MT1/MT2 agonist | Sedation, hypotension (generally low toxicity in overdose) |
| Symptom | First-line |
|---|---|
| Acute dystonia | Diphenhydramine 25–50 mg IV/IM/PO or benztropine 1–2 mg IV/IM |
| Refractory dystonia | Lorazepam 1–2 mg IV, repeat in 15–20 min |
| Akathisia | Benztropine; if insufficient — propranolol 40–80 mg/day |
| Drug-induced parkinsonism | Minimize dose; anticholinergic agent as above |
| Criteria | Disposition |
|---|---|
| Asymptomatic, normal ECG at 6 hours | Observation, consider psychiatric evaluation |
| Symptomatic (sedation, hypotension, QTc > 500) | ICU admission |
| Intubated or hemodynamically unstable | ICU |
| EPS without systemic toxicity | ED treatment + monitored observation |